Clinical Ophthalmology (Dec 2022)

Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting

  • Ackerman M,
  • Lawless M,
  • Levitz L,
  • Bhatt U,
  • Reich JA,
  • Sutton G,
  • Roberts TV,
  • Tenen A,
  • Kaur A,
  • Hodge C

Journal volume & issue
Vol. Volume 16
pp. 4227 – 4237

Abstract

Read online

Mariska Ackerman,1 Michael Lawless,2,3 Lewis Levitz,4 Uday Bhatt,4 Joseph A Reich,4 Gerard Sutton,2,3 Timothy V Roberts,2,3 Abi Tenen,4 Amanpreet Kaur,4 Chris Hodge2,3,5,6 1Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; 2Vision Eye Institute, Sydney, New South Wales, Australia; 3Save Sight Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; 4Vision Eye Institute, Melbourne, Victoria, Australia; 5Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia; 6Macquarie University, Sydney, AustraliaCorrespondence: Michael Lawless, Vision Eye Institute, Level 3 270 Victoria Avenue, Chatswood, Sydney, NSW, 2067, Australia, Tel +61 2 9424 9999, Fax +61 2 9410 3000, Email [email protected]: Trifocal Intraocular Lenses (IOLs) were developed to provide patients with effective near, intermediate and distance vision, thus minimizing spectacle dependency. Residual astigmatism has previously been shown to impact unaided visual acuity across all distances; therefore, to optimise the expected outcomes, consideration of preoperative corneal astigmatism is essential. The purpose of this study was to provide a real-world, multi-site review of visual and refractive outcomes in eyes undergoing implantation with the Panoptix Trifocal toric IOL platform.Patients and Methods: This study represents a two-fold approach. Patients who had previously undergone routine cataract removal and IOL insertion with the Panoptix Toric IOL were retrospectively analysed for routine efficacy and safety endpoints (“Retrospective Cohort”). Data was retrieved from the preoperative, surgical and postoperative visits (range 2– 6 weeks). A further subset of patients undergoing lens removal and bilateral Panoptix Toric IOL insertion were identified at surgery (“Qualitative Cohort”). These patients underwent additional testing inclusive of quality of vision questionnaire and bilateral defocus curve.Results: A total of 466 eyes of 254 patients were included in the retrospective cohort. Between 91% and 98% of eyes, respectively, were within 0.50D and 1.00D of target. Mean absolute difference from Spherical Equivalent (SE) target was 0.22 ± 0.24Ds. Following surgery, 94% of eyes demonstrated a refractive astigmatism of 0.50D or less. Further, 61% eyes achieved uncorrected distance visual acuity (UDVA) of 20/20 or better, increasing to 94% achieving 20/32 or better. Seventy percent of eyes unilaterally achieved N5 unaided and 66.0% achieved N8 or better at intermediate. In the qualitative cohort, no patient described any symptom as significant or requested explant.Conclusion: In a real-world setting, the PanOptix toric trifocal IOL continues to demonstrate refractive accuracy and good visual performance at all focal distances. This IOL also exhibited good quality of vision, with minimally bothersome visual disturbances or photic phenomena.Keywords: cataract surgery, IOL, trifocal, lens extraction, visual acuity

Keywords